Creative Planning decreased its holdings in shares of Humana Inc. (NYSE:HUM – Free Report) by 8.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,245 shares of the insurance provider’s stock after selling 2,273 shares during the quarter. Creative Planning’s holdings in Humana were worth $7,680,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in HUM. Pzena Investment Management LLC boosted its stake in Humana by 538.7% in the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after buying an additional 1,955,375 shares during the last quarter. Davis Selected Advisers boosted its position in shares of Humana by 16.1% in the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock worth $863,640,000 after acquiring an additional 321,233 shares during the last quarter. Marshall Wace LLP grew its holdings in Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after purchasing an additional 774,085 shares during the period. Legal & General Group Plc grew its holdings in Humana by 2.1% in the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock valued at $442,396,000 after purchasing an additional 24,842 shares during the period. Finally, Ontario Teachers Pension Plan Board increased its position in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after purchasing an additional 1,050,459 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on HUM shares. Sanford C. Bernstein raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a research note on Tuesday, October 8th. KeyCorp began coverage on shares of Humana in a research report on Friday, October 11th. They set a “sector weight” rating for the company. Leerink Partners lowered Humana from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research note on Thursday, October 3rd. Finally, Oppenheimer decreased their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. One research analyst has rated the stock with a sell rating, nineteen have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $315.33.
Humana Stock Performance
Humana stock opened at $258.61 on Thursday. The company has a market cap of $31.16 billion, a PE ratio of 16.10, a P/E/G ratio of 1.91 and a beta of 0.50. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $527.18. The company has a fifty day moving average price of $310.28 and a two-hundred day moving average price of $337.43. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66.
Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The business had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $8.94 EPS. Research analysts expect that Humana Inc. will post 16.06 earnings per share for the current year.
Humana Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.37%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio (DPR) is 22.04%.
Humana Company Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
- Five stocks we like better than Humana
- Comparing and Trading High PE Ratio Stocks
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What Are the U.K. Market Holidays? How to Invest and Trade
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Stock Average Calculator
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.